We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+9.11%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$7.02B
AUM Growth
+$483M
Cap. Flow
+$199M
Cap. Flow %
2.83%
Top 10 Hldgs %
49.95%
Holding
78
New
10
Increased
26
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$122M
2
ZLAB icon
Zai Lab
ZLAB
+$78.9M
3
DGX icon
Quest Diagnostics
DGX
+$69.7M
4
ABT icon
Abbott
ABT
+$58.5M
5
JBIO
Jade Biosciences
JBIO
+$49.3M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$149M
2
AKRO
Akero Therapeutics
AKRO
+$88.2M
3
GMED icon
Globus Medical
GMED
+$82.3M
4
ALKS icon
Alkermes
ALKS
+$65.5M
5
ARVN icon
Arvinas
ARVN
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DGX icon
26
Quest Diagnostics
DGX
$26.3B
$89.8M 1.28%
500,000
+401,003
+405% +$69.7M
QURE icon
27
uniQure
QURE
$3.15B
$71.9M 1.02%
5,158,231
+892,803
+21% +$12M
GHRS icon
28
GH Research
GHRS
$2.1B
$67.5M 0.96%
5,540,457
+40,688
+0.7% +$446K
URGN icon
29
UroGen Pharma
URGN
$2.22B
$62.3M 0.89%
4,543,895
+709,101
+18% +$6.8M
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.54B
$62.1M 0.88%
1,707,402
– –
ABT icon
31
Abbott
ABT
$187B
$60.4M 0.86%
+444,000
New +$58.5M
STOK icon
32
Stoke Therapeutics
STOK
$2.06B
$58.2M 0.83%
5,123,525
– –
TSHA icon
33
Taysha Gene Therapies
TSHA
$1.82B
$57.8M 0.82%
25,021,584
+6,233,718
+33% +$13.5M
SYRE icon
34
Spyre Therapeutics
SYRE
$9.12B
$54.2M 0.77%
3,621,996
– –
BBNX
35
Beta Bionics
BBNX
$635M
$48M 0.68%
3,299,191
-679
-0% -$9.61K
GEHC icon
36
GE HealthCare
GEHC
$31.8B
$46.4M 0.66%
626,000
+106,000
+20% +$7.38M
GH icon
37
Guardant Health
GH
$21.1B
$44.6M 0.63%
+856,501
New +$38.3M
CGON icon
38
CG Oncology
CGON
$6.6B
$44.2M 0.63%
1,701,216
– –
RCKT icon
39
Rocket Pharmaceuticals
RCKT
$387M
$43.3M 0.62%
17,687,772
– –
IMTX icon
40
Immatics
IMTX
$1.29B
$37.5M 0.53%
6,970,152
+60,642
+0.9% +$301K
SLNO
41
DELISTED
Soleno Therapeutics
SLNO
$35.6M 0.51%
+424,408
New +$31.8M
MLTX icon
42
MoonLake Immunotherapeutics
MLTX
$1.53B
$35M 0.5%
+741,090
New +$30.2M
TEM
43
Tempus AI
TEM
$8.32B
$25.4M 0.36%
400,000
– –
LENZ
44
LENZ Therapeutics
LENZ
$164M
$25.3M 0.36%
863,389
– –
CMPS
45
Compass Pathways
CMPS
$1.83B
$23M 0.33%
8,221,929
+2,683,761
+48% +$10.1M
OBIO icon
46
Orchestra BioMed
OBIO
$249M
$22.3M 0.32%
8,306,062
+99,900
+1% +$292K
ORKA
47
Oruka Therapeutics
ORKA
$5.94B
$21.8M 0.31%
1,945,649
– –
NGNE icon
48
Neurogene
NGNE
$710M
$20.4M 0.29%
1,362,456
+13,800
+1% +$217K
CNTA
49
DELISTED
Centessa Pharmaceuticals
CNTA
$20.1M 0.29%
1,529,836
+1,479,836
+2,960% +$18.7M
ETNB
50
DELISTED
89bio
ETNB
$19.3M 0.28%
1,967,527
– –
1
2
3 4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

RTW Investments's Q2 2025 Portfolio in Review

As of Q2 2025, RTW Investments held 78 positions worth $7.02B, up 7.4% from $6.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments's Q2 2025 filing shows 10 new, 26 increased, 8 reduced and 5 closed positions. Its largest new stake was Neurocrine Biosciences: 1,062,072 shares worth $133M. The largest sale was Axsome Therapeutics, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q2 2025 buy was Neurocrine Biosciences: 1,062,072 shares worth $133M.
  • RTW Investments added most to Zai Lab in Q2 2025, an estimated $78.9M increase.
  • RTW Investments's biggest Q2 2025 reduction was Axsome Therapeutics, cutting an estimated $149M.
  • RTW Investments fully exited Globus Medical in Q2 2025, selling an estimated $82.3M.
  • RTW Investments's ten largest holdings make up 50% of its $7.02B portfolio in Q2 2025.
  • RTW Investments opened 10 new positions and closed 5 in Q2 2025.
  • RTW Investments's portfolio value rose 7.4% quarter-over-quarter to $7.02B.

Based on RTW Investments's 13F filing for Q2 2025, filed 14 Aug 2025.